IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6531-6541

  Shimizu, Takatsune ^a,b,c   Sugihara, Eiji ^b,c   Yamaguchi Iwai, Sayaka ^b,d   Tamaki, Sakura ^e   Koyama, Yuko ^e   Kamel, Walied ^a,d,f   Ueki, Arisa ^b   Ishikawa, Tomoki ^b,g   Chiyoda, Tatsuyuki ^b   Osuka, Satoru ^b   Onishi, Nobuyuki ^b   Ikeda, Hiroko ^a   Kamei, Junzo ^a   Matsuo, Koichi ^d   Fukuchi, Yumi ^a   Nagai, Toshihiro ^d   Toguchida, Junya ^e,h,i   Toyama, Yoshiaki ^d   Muto, Akihiro ^a   Saya, Hideyuki ^b,c  

^a HOSHI UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f Mansoura University   (Egypt)

^g DAIICHI SANKYO CO   (Japan)

^h KYOTO UNIVERSITY   (Japan)

ⁱ KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLINE; DOXORUBICIN; GLUTAMINE; HISTONE H2AX; KI 67 ANTIGEN; PROTEIN KINASE B; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR; INSULIN;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOPHAGY; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DORMANCY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRESCHOOL CHILD; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; YOUNG ADULT; ANIMAL; BONE NEOPLASMS; C57BL MOUSE; DRUG RESISTANCE; METABOLISM; OSTEOSARCOMA; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADOLESCENT; ADULT; ANIMALS; AUTOPHAGY; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHILD; CYTOPROTECTION; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTAMINE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE; MICE, INBRED C57BL; OSTEOSARCOMA;

EID: 84918576050     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0914     Document Type: Article

References (44)

1. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 2008;10:315-27.
2. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol 2010;21 Suppl 7: vii320-5.
3. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009;152:239-62.
4. Redmond KM, Wilson TR, Johnston PG, Longley DB. Resistance mechanisms to cancer chemotherapy. Front Biosci 2008;13:5138-54.
5. Garraway LA, Janne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012;2:214-26.
6. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006;94:1087-92.
7. Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual differences in drug response. Clin Pharmacol Ther 2012;92:727-36.
8. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008;3:e2428.
9. Tehranchi R, Woll P, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ. Persistent malignant stem cells in del (5q) myelodysplasia in remission. N Engl J Med 2010;363:1025-37.
10. Li X, Lewis MT, Huang J, Gutierrez C, Osborne K, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-9.
11. Shimizu T, Ishikawa T, Sugihara E, Kuninaka S, Miyamoto T, Mabuchi Y, et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010;29:5687-99.
12. Shimizu T, Ishikawa T, Iwai S, Ueki A, Sugihara E, Onishi N, et al. Fibroblast growth factor-2 is an important factor that maintains cellular immaturity and contributes to aggressiveness of osteosarcoma. Mol Cancer Res 2012;10:454-68.
13. Chiyoda T, Sugiyama N, Shimizu T, Naoe H, Kobayashi Y, Ishizawa J, et al. LATS1/WARTS phosphorylates MYPT1 to counteract PLK1 and regulate mammalian mitotic progression. J Cell Biol 2012;197:625-41.
14. Ogawa Y, Yamazaki K, Kuwana M, Mashima Y, Nakamura Y, Ishiba S, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci 2001;42:111-9.
15. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.
16. Valeriote F, Van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res 1975;35:2619-30.
17. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WN. DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
18. Rogakou EP, Boon C, Redon C, Bonner WN. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999;146:905-16.
19. Luo W, Kinsey M, Schiffman JD, Lessnick SL. Glutathione s-transferases in pediatric cancer. Front Oncol 2011;1; 1-11.
20. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720-8.
21. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011;147:728-41.
22. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011;10:1533-41.
23. Tanida I, Mizushima N, Kiyooka M, Ohsumi M, Ueno T, Ohsumi Y, et al. Apg7p/Cvt2p: a novel protein-activating enzyme essential for autophagy. Mol Biol Cell 1999;10:1367-79.
24. Oettgen HF, Old LJ, Boyse EA, Campbell HA, Philips FS, Clarkson BD, et al. Inhibition of leukemia in man by L-asparaginase. Cancer Res 1967;27:2619-31.
25. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/Angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004;118:149-61.
26. Ema H, Suda T. Two anatomically distinct niches regulate stem cell activity. Blood 2012;120:2174-81.
27. Adam AP, George A, Schewe D, Bragado P, Iglesias BV, Ranganathan AC, et al. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res 2009;69:5664-72.
28. Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA. Erk1/2 and p38a/b signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res 2011;17:5850-7.
29. Chandarlapaty S. Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov 2012;2:311-9.
30. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000;14:783-94.
31. Tremblay F, Brule S, Um SH, Li Y, Masuda K, Roden M, et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci USA 2007;104:14056-61.
32. Tanti JF, Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 2009;9:753-62.
33. Li B, Tsao SW, Chan KW, Ludwig DL, Novosyadlyy R, Li YY, et al. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance - Implications for IGF-II and IGF-1R-targeted therapy. Clin Cancer Res 2014;20:2651-62.
34. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 2009;69:2443-52.
35. Pollak MN, Polychronakos C, Richard M. Insulin like growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 1990;82:301-5.
36. Pollak M, Sem AW, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 1992;84:966-71.
37. MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004;92:77-91.
38. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of the angiogenic switch concept. Leukemia 2007;21:44-52.
39. Van Der Vos KE, Eliasson P, Cezanne TP, Vervoort SJ, Van Boxtel R, Putker M, et al. Modulation of glutamine metabolism by the PI (3) KPKB-FOXO network regulates autophagy. Nature Cell Biol 2012;14:829-37.
40. Sakiyama T, Musch MW, Ropeleski MJ, Tsubouchi H, Chang EB. Glutamine increases autophagy under basal and stressed conditions in intestinal epithelial cells. Gasteroenterology 2009;136:924-32.
41. Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, et al. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature 2013;494:323-9.
42. Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, Sadighi-Akha E, et al. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med 2011;208:455-67.
43. Lemons JM S, Feng XJ, Bennett BD, Legesse-Miller A, Johnson EL, Raitman I, et al. Quiescent fibroblasts exhibit high metabolic activity. PLoS Biol 2010;8:e1000514.
44. Dorr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Dabritz HM, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 2013;501:421-5.